ECSP066396A - Peptidos y compuestos que se unen a un receptor - Google Patents

Peptidos y compuestos que se unen a un receptor

Info

Publication number
ECSP066396A
ECSP066396A EC2006006396A ECSP066396A ECSP066396A EC SP066396 A ECSP066396 A EC SP066396A EC 2006006396 A EC2006006396 A EC 2006006396A EC SP066396 A ECSP066396 A EC SP066396A EC SP066396 A ECSP066396 A EC SP066396A
Authority
EC
Ecuador
Prior art keywords
peptides
compounds
join
receiver
tpo
Prior art date
Application number
EC2006006396A
Other languages
English (en)
Inventor
Brian R Macdonald
Jeffery Kenneth Weis
Edward John Yurkow
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34272720&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP066396(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Publication of ECSP066396A publication Critical patent/ECSP066396A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/524—Thrombopoietin, i.e. C-MPL ligand
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Polyethers (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describen péptidos y compuestos que se unen a, y activan el receptor de la trombopoyetina (c-mpl o TPO-R) o actúan de otra manera como un antagonista de la TPO.
EC2006006396A 2003-08-28 2006-02-24 Peptidos y compuestos que se unen a un receptor ECSP066396A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US49874003P 2003-08-28 2003-08-28

Publications (1)

Publication Number Publication Date
ECSP066396A true ECSP066396A (es) 2006-08-30

Family

ID=34272720

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2006006396A ECSP066396A (es) 2003-08-28 2006-02-24 Peptidos y compuestos que se unen a un receptor

Country Status (32)

Country Link
US (1) US7576056B2 (es)
EP (1) EP1675606B1 (es)
JP (1) JP4848277B2 (es)
KR (2) KR101183875B1 (es)
CN (2) CN102241742B (es)
AR (1) AR045530A1 (es)
AU (1) AU2004270656B2 (es)
BR (1) BRPI0414008B8 (es)
CA (1) CA2537421C (es)
CY (1) CY1118965T1 (es)
DK (1) DK1675606T3 (es)
EA (1) EA009286B1 (es)
EC (1) ECSP066396A (es)
ES (1) ES2626107T3 (es)
HR (1) HRP20170810T1 (es)
HU (1) HUE032370T2 (es)
IL (1) IL173965A (es)
IS (1) IS8300A (es)
LT (1) LT1675606T (es)
ME (1) ME00313B (es)
MX (1) MXPA06002292A (es)
NO (1) NO344233B1 (es)
NZ (1) NZ545455A (es)
PL (1) PL1675606T3 (es)
PT (1) PT1675606T (es)
RS (2) RS56387B1 (es)
SG (1) SG131110A1 (es)
SI (1) SI1675606T1 (es)
TW (1) TWI348375B (es)
UA (1) UA82710C2 (es)
WO (1) WO2005023834A2 (es)
ZA (1) ZA200602495B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7091311B2 (en) * 1996-06-07 2006-08-15 Smithkline Beecham Corporation Peptides and compounds that bind to a receptor
DK2319928T3 (da) 1998-10-23 2013-06-24 Kirin Amgen Inc Dimere trombopoietiske peptidomimetika, der binder til MPL-receptor og har trombopoietisk aktivitet
MXPA05003057A (es) * 2002-09-18 2006-04-18 Johnson & Johnson Metodos para aumentar la produccion de celulas madre hematopoyeticas y plaquetas.
US20040149235A1 (en) * 2002-10-04 2004-08-05 Pogue Albert S. Apparatus and method for removal of waste from animal production facilities
RS56387B1 (sr) 2003-08-28 2017-12-29 Ortho Mcneil Pharm Inc Peptidi i jedinjenja koja se vežu za trombopoetinski receptor
US7723295B2 (en) * 2003-08-28 2010-05-25 Ortho-Mcneil Pharmaceutical, Inc. Peptides and compounds that bind to a receptor
US7615533B2 (en) 2004-08-16 2009-11-10 Janssen Pharmaceutica N.V. TPO peptide compounds for treatment of anemia
EP1986677A2 (en) * 2006-01-25 2008-11-05 Amgen Inc. Thrombopoietic compounds
AR059573A1 (es) * 2006-02-14 2008-04-16 Janssen Pharmaceutica Nv Uso de compuestos peptidicos de tpo y composiciones farmaceuticas en el tratamiento de la anemia
PT1984014E (pt) * 2006-02-14 2014-11-13 Janssen Pharmaceutica Nv Utilização de compostos de péptidos tpo e composições farmacêuticas no tratamento da anemia
US7981425B2 (en) 2006-06-19 2011-07-19 Amgen Inc. Thrombopoietic compounds
US20090311344A1 (en) * 2008-06-03 2009-12-17 Yurkow Edward J Dosing Regimen
JP5709113B2 (ja) 2011-06-23 2015-04-30 株式会社島津製作所 分岐型両親媒性ブロックポリマー、それを用いた分子集合体及び薬剤搬送システム
KR102688415B1 (ko) 2017-07-26 2024-07-24 잔센파마슈티카엔.브이. 표적화된 방사선 치료요법에 의해 유도된 혈관 무결성을 보호하는 조성물
JP2022523663A (ja) 2019-01-25 2022-04-26 ヤンセン ファーマシューティカ エヌ．ベー． 放射線処置および／または放射線模倣剤処置を伴う、肝損傷を緩和し、肝臓の肥厚、再生、および細胞の生着を促進するための方法
MX2021008928A (es) 2019-01-25 2021-11-04 Janssen Pharmaceutica Nv Métodos para mejorar la protección contra lesiones vasculares y de organos, la recuperación hematopoyética y la supervivencia en respuesta a la radiacion corporal total/exposicion química.
US11273203B2 (en) 2019-01-25 2022-03-15 Janssen Pharmaceutica Nv Methods of mitigating toxic effects of vesicants and caustic gas
WO2023056444A1 (en) 2021-10-01 2023-04-06 Janssen Pharmaceutica N.V. Methods of increasing progenitor cell production
WO2024095178A1 (en) 2022-11-01 2024-05-10 Janssen Pharmaceutica Nv Thrombopoietin mimetic for use in the treatment of acute liver failure

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5326558A (en) 1989-08-08 1994-07-05 Genetics Institute, Inc. Megakaryocytopoietic factor
IL96477A0 (en) 1989-12-01 1991-08-16 Amgen Inc Megakaryocyte production
DK167813B1 (da) 1989-12-07 1993-12-20 Carlbiotech Ltd As Pentapeptidderivat, farmaceutisk acceptable salte heraf, fremgangsmaade til fremstilling deraf og farmaceutisk praeparat indeholdende et saadant derivat
US5571508A (en) 1989-12-18 1996-11-05 Amrad Corporation Limited Method for the treatment of thrombocytopenia and pharmaceutical compositions useful therefor
IT1241395B (it) 1990-04-02 1994-01-10 Eniricerche Spa Composti immunogenici,il procedimento per la loro sintesi e loro impiego per la preparazione di vaccini antimalaria
US5141851A (en) 1990-04-18 1992-08-25 Board Of Regents, The University Of Texas System Isolated farnesyl protein transferase enzyme
US5250732A (en) 1991-07-18 1993-10-05 Genentech, Inc. Ketamine analogues for treatment of thrombocytopenia
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
WO1993025221A1 (en) 1992-06-11 1993-12-23 Alkermes Controlled Therapeutics, Inc. Erythropoietin drug delivery system
EP0673387B1 (en) 1992-12-11 1999-09-22 University Of Florida Materials and methods for control of pests
AU8124694A (en) 1993-10-29 1995-05-22 Affymax Technologies N.V. In vitro peptide and antibody display libraries
SG47030A1 (en) 1994-01-03 1998-03-20 Genentech Inc Thrombopoietin
WO1995021919A2 (en) 1994-02-14 1995-08-17 Kirin Brewery Company, Limited Protein having tpo activity
AU691828B2 (en) 1994-02-14 1998-05-28 University Of Washington Hematopoietic protein and materials and methods for making it
SG79882A1 (en) 1994-02-14 2001-04-17 Kirin Brewery Protein having tpo activity
CA2169173C (en) 1994-02-14 2002-10-15 Kenneth Kaushansky Methods for stimulating erythropoiesis using thrombopoietin
US5766581A (en) 1994-03-31 1998-06-16 Amgen Inc. Method for treating mammals with monopegylated proteins that stimulates megakaryocyte growth and differentiation
US5571686A (en) 1994-04-14 1996-11-05 Massachusetts Institute Of Technology Method of using megapoietin for prolonging the survival & viability of platlets
WO1996014293A1 (en) * 1994-11-04 1996-05-17 Santen Pharmaceutical Co., Ltd. Novel 1,3-dialkylurea derivative having hydroxyl group
AU4163196A (en) 1994-11-30 1996-06-19 Zymogenetics Inc. Low molecular weight thrombopoietin
US5641655A (en) 1994-11-30 1997-06-24 Zymogenetics, Inc. Methods for producing thrombopoietin polypeptides using a mammalian tissue plasminogen activator secretory peptide
DE69636714T2 (de) 1995-04-26 2007-10-18 Kyowa Hakko Kogyo Co., Ltd. G-CSF TPO Fusionsproteine
US6251864B1 (en) * 1995-06-07 2001-06-26 Glaxo Group Limited Peptides and compounds that bind to a receptor
US5869451A (en) * 1995-06-07 1999-02-09 Glaxo Group Limited Peptides and compounds that bind to a receptor
ES2303338T3 (es) * 1995-06-07 2008-08-01 Glaxo Group Limited Peptidos y compuestos que se unen a un receptor de trombopoyetina.
US6060052A (en) 1995-10-30 2000-05-09 Systemix, Inc. Methods for use of Mpl ligands with primitive human hematopoietic stem cells
US5932546A (en) 1996-10-04 1999-08-03 Glaxo Wellcome Inc. Peptides and compounds that bind to the thrombopoietin receptor
DE60032783T2 (de) 1999-09-24 2007-12-06 Smithkline Beecham Corp. Thrombopoietinmimetika
DE60123115T2 (de) * 2000-12-22 2007-03-29 Ipsen Manufacturing Ireland Ltd. Verfahren für die synthese eines lhrh peptides
AU2002307062A1 (en) 2001-04-02 2002-10-15 Purdue Pharma L.P. Thrombopoietin (tpo) synthebody for stimulation of platelet production
MXPA05003057A (es) * 2002-09-18 2006-04-18 Johnson & Johnson Metodos para aumentar la produccion de celulas madre hematopoyeticas y plaquetas.
RS56387B1 (sr) 2003-08-28 2017-12-29 Ortho Mcneil Pharm Inc Peptidi i jedinjenja koja se vežu za trombopoetinski receptor

Also Published As

Publication number Publication date
JP4848277B2 (ja) 2011-12-28
WO2005023834A3 (en) 2005-05-06
KR101183875B1 (ko) 2012-09-27
BRPI0414008B1 (pt) 2018-05-15
NZ545455A (en) 2009-02-28
MEP48508A (en) 2011-02-10
BRPI0414008A (pt) 2006-10-24
US20050137133A1 (en) 2005-06-23
ME00313B (me) 2011-05-10
RS20060141A (sr) 2008-08-07
UA82710C2 (uk) 2008-05-12
AR045530A1 (es) 2005-11-02
CN1871022B (zh) 2011-07-06
ES2626107T3 (es) 2017-07-24
CY1118965T1 (el) 2018-01-10
EA009286B1 (ru) 2007-12-28
SI1675606T1 (sl) 2017-07-31
RS56387B1 (sr) 2017-12-29
PL1675606T3 (pl) 2017-08-31
EP1675606B1 (en) 2017-04-05
CA2537421C (en) 2011-09-27
CN102241742A (zh) 2011-11-16
AU2004270656B2 (en) 2011-03-10
AU2004270656A1 (en) 2005-03-17
DK1675606T3 (en) 2017-06-19
EP1675606A4 (en) 2009-09-30
IL173965A (en) 2015-10-29
IL173965A0 (en) 2006-07-05
CN1871022A (zh) 2006-11-29
NO20061346L (no) 2006-05-22
IS8300A (is) 2006-02-14
HUE032370T2 (en) 2017-09-28
CN102241742B (zh) 2014-04-02
BRPI0414008B8 (pt) 2021-05-25
KR20120078742A (ko) 2012-07-10
CA2537421A1 (en) 2005-03-17
US7576056B2 (en) 2009-08-18
ZA200602495B (en) 2007-06-27
EP1675606A2 (en) 2006-07-05
KR20070017942A (ko) 2007-02-13
MXPA06002292A (es) 2006-09-04
HRP20170810T1 (hr) 2017-08-11
SG131110A1 (en) 2007-04-26
EA200600477A1 (ru) 2007-02-27
JP2007504132A (ja) 2007-03-01
TW200517103A (en) 2005-06-01
TWI348375B (en) 2011-09-11
LT1675606T (lt) 2017-11-10
NO344233B1 (no) 2019-10-14
PT1675606T (pt) 2017-05-22
HK1096873A1 (en) 2007-06-15
WO2005023834A2 (en) 2005-03-17

Similar Documents

Publication Publication Date Title
ECSP066396A (es) Peptidos y compuestos que se unen a un receptor
ECSP088169A (es) Peptidos y compuestos que se unen a un receptor
CY1118343T1 (el) Αντισωματα συνδεσης twεακ
EP1630152A4 (en) CONDENSED CYCLIC COMPOUND
NL1027434A1 (nl) Bicyclische pyrazolyl- en imidazolylverbindingen, en toepassingen daarvan.
FR2884516B1 (fr) Antagonistes npy, preparation et utilisations
DK1749921T3 (da) Brandhæmmende, syntetisk læder
EA200601759A1 (ru) Композиции рамиприла
ATE410428T1 (de) Pyrroloä2,1-cüä1,4übenzodiazepine als vasopressin-agonisten
ES1057855Y (es) Escenario movil.
NL1031525A1 (nl) 7-Fluor-1,3-dihydroindool-2-onoxazolidinonen als antibacteriele middelen.
ES1055317Y (es) Escenario autotransportable.
DOP2002000515A (es) Lactamas como antagonista de taquiquininas.
ITBO20030177A1 (it) Calza traspirante.
FR2883012B1 (fr) Construction mobile ou fixe, pliable
ATE517821T1 (de) Behälter
UY27183A1 (es) -novedosos derivados de pirimidinona sustituidos que se combinan con receptores de integrina, su preparación y su uso.
BRPI0401530B1 (pt) fertilizadora de uso combinado.
ES1058250Y (es) Protector de ropa.
ES1057380Y (es) Premarco.
FIU20050381U0 (fi) Kompakti konepistooli-konstruktio
ITMO20040313A1 (it) Mostarda di carpi detta fina.
ES1061217Y (es) Barrera extensible.
ES1051527Y (es) Carpeta compartimentada.
ES1057381Y (es) Calcetin.